Enopace Biomedical is an early-stage medical device company developing a miniature, implantable endovascular micro-stimulator and neuromodulation system intended to increase cardiac efficiency by reducing left ventricular workload in heart failure patients. The technology is being positioned to expand device-based therapy options for the large unmet need of heart failure. The company was founded in 2008, is based in Caesarea, Israel, and is led by CEO Amir Dagan. Enopace was seeded and is owned by Rainbow Medical, which has backed multiple med‑tech ventures. Sorin Group executed an initial investment in October 2011 and is now providing further financing to support ongoing development and testing. The current financing is structured as a minority investment with milestone-triggered follow‑on funding and includes an exclusive option for Sorin to acquire the company in the future. Enopace Biomedical is an early-stage medical device company developing a minimally invasive, implantable neurostimulation system intended to increase cardiac efficiency by reducing left ventricular workload in congestive heart failure patients. The device targets an unmet need in heart failure treatment, including patient segments not served by cardiac resynchronization therapy. Sorin Group’s $7 million investment will finance the company’s initial clinical studies and ongoing product development. Rainbow Medical founded and seeded Enopace in 2008 and remains an investor. The company is led by CEO Amir Dagan and is based in Caesarea, Israel. No revenue or user metrics are disclosed in the article.

Total raised

$12M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2013